BOM:532523

5 stories mentioning BOM:532523Updated 7d ago

Every FINWIRES story that references BOM:532523, newest first.

Biocon to Buy 37.8% Stake in Renewable Energy Firm Ampin C&I Power Twelve

Indian pharmaceutical company Biocon (NSE:BIOCON, BOM:532523) has agreed to acquire a 37.8% stake in renewable energy company Ampin C&I Power Twelve for 54.8 million Indian rupees, according to a Wednesday filing to the Indian stock exchanges.Biocon will subscribe to around 5.5 million equity shares of AMPIN at a face value of 10 rupees each, with allotment expected in due course.Following subsequent capital infusions by other entities into the project, Biocon's shareholding will be diluted to 15.9%.AMPIN is a special-purpose vehicle established to generate renewable energy. It is currently setting up a 27.12 MW (DC) solar power plant in Karnataka, India.

BOM:532523NSE:BIOCON

Asia37d ago

Biocon Arm Gets Health Canada Approval for Micafungin Injection

Biocon (NSE:BIOCON, BOM:532523) subsidiary, Biocon Pharma, has secured Health Canada's approval for micafungin for injection in 50 mg and 100 mg strengths, according to a Monday filing.The drug is indicated for treatment of certain infections in adults and children aged four months and above, according to the filing. These include candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses, as well as esophageal candidiasis

BOM:532523NSE:BIOCON

Asia41d ago

Biocon Posts Lower Fiscal Q4 Consolidated Profit

Biocon (NSE:BIOCON, BOM:532523) consolidated attributable profit declined sharply in the fiscal fourth quarter to 1.26 billion Indian rupees from 3.45 billion rupees a year ago, according to an Indian bourse filing on Thursday by the pharmaceutical company.Earnings per share in the quarter ended March 31 slipped to 0.79 rupees compared with the year-ago figure of 2.87 rupees.Revenue from operations in fiscal Q4, however, increased year on year to 45.2 billion rupees from 44.2 billion rupees.The company's board recommended a final dividend of 0.50 rupees per share for the financial year ended March 31. The proposed dividend is payable on Aug.31 to shareholders of record on July 3, the filing said.

BOM:532523NSE:BIOCON

Asia49d ago

Biocon Receives Five Observations from US FDA After Bengaluru, India, Unit Inspection

Biocon (NSE:BIOCON, BOM:532523) has received five observations from the US Food and Drug Administration (US FDA) after the pre-license inspection at Biocon's biosimilars site in Bengaluru, India, according to a Thursday filing to the Indian stock exchanges.The US FDA inspected the unit between April 20 and April 29 and covered three biologics manufacturing units, five quality testing laboratories, and two warehouses.At the conclusion of the inspection, the U.S. FDA issued a Form 483 with five observations, which the company said are procedural in nature and do not pertain to data integrity or quality oversight.There were no repeat observations noted, Biocon said.The company's shares were down over 1% in recent trade.

BOM:532523NSE:BIOCON

Asia58d ago

Biocon Gets Health Canada Approval for Biosimilars Bosaya, Vevzuo

Biopharmaceutical company Biocon (NSE:BIOCON, BOM:532523) has received a notice of compliance from Health Canada for Bosaya (denosumab) and Vezuo (denosumab), according to a Tuesday filing to the Indian stock exchanges.Bosaya is a biosimilar to Prolia and is most commonly presented as a 60 mg/mL injection for subcutaneous use in a prefilled syringe. Meanwhile, Vezuo, a biosimilar to Xgeva, is mostly presented as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial.Denosumab products help improve bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.The company's shares were up nearly 1% in recent trade.

BOM:532523NSE:BIOCON

Track with the FINWIRES app suite

FolioX

Track BOM:532523 in your portfolio

WheelAI

Analyze BOM:532523 options with the wheel strategy

StockInsider

See market sentiment on BOM:532523